Company

Turning Point Therapeutics, Inc.

Turning Point Therapeutics develops targeted cancer therapies, and Bristol-Myers Squibb Company acquired the company in August 2022.

About

Turning Point Therapeutics, Inc. develops targeted cancer treatments using biological and small molecule therapies. Founded in 2013 and headquartered in San Diego, US, the company is led by CEO Athena Countouriotis, has engaged in 10 deals and has raised USD 4.1 bn in total funding. Its most recent round was a Trade Sale in August 2022, in which Bristol-Myers Squibb Company acquired the company; in 2021 it reported revenue of USD 30.83 mn and an EBITDA loss of USD 229.91 mn.

3Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in